OmniaBio
OmniaBio is a Canadian contract development and manufacturing organization (CDMO) that specializes in cell and gene therapy. Established on July 1, 2022, as a subsidiary of CCRM, the company is dedicated to advancing life-saving therapies by offering a full range of services from early process development to commercial-scale manufacturing. The company provides services such as process development, analytical development, and GMP manufacturing, ensuring compliance for clinical and commercial supply. OmniaBio has expertise in both autologous and allogeneic manufacturing and utilizes advanced technologies, including artificial intelligence and robotics, to create efficient manufacturing processes. With a focus on personalized client services, OmniaBio supports its partners with dedicated project management and real-time data sharing. Headquartered in Hamilton, Ontario, OmniaBio serves a global customer base, including clinical-stage biopharmaceutical companies and research organizations. The company collaborates with various partners to develop innovative therapies, aiming to enhance the affordability and accessibility of transformative treatments worldwide.
Work at OmniaBio in HR or recruiting? Claim this page
Headcount trend
OmniaBio went from 55 employees in Jul 2023 to 135 in Jun 2025. Jan to Jun 2025: 34 people joined, 7 left.
Headcount data through Jun 2025
Funding rounds
| Date | Round | Money raised | No. | Investors |
|---|---|---|---|---|
| May 2022 | Funding | $90M | 1 |
Org structure
Headcount by department
Peer reviews
Worked with someone at OmniaBio?
Anonymous peer reviews on OffTheRecord
Similar companies
OmniaBio FAQ
How many employees does OmniaBio have?
OmniaBio has about 135 employees, up 7.1% over the 3 months to Jun 2025.
How much funding has OmniaBio raised?
OmniaBio has raised $90M in total funding.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.